Cullinan Therapeutics (CGEM) Initial Form 3 Shows Zero Beneficial Ownership
Rhea-AI Filing Summary
Cullinan Therapeutics (CGEM) Form 3: Andrew R. Allen filed an initial Section 16 statement on behalf of himself as a director of Cullinan Therapeutics reporting the event date 08/07/2025. The filing states that no securities are beneficially owned by the reporting person. The form was signed by an attorney-in-fact, Jacquelyn Sumer, on 08/08/2025. No derivative or non-derivative holdings are listed.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did the Form 3 filed for Cullinan Therapeutics (CGEM) report?
The Form 3 reports that Andrew R. Allen, a director, filed an initial beneficial ownership statement and no securities are beneficially owned.
Who is the reporting person on the Form 3 for CGEM?
The reporting person is Andrew R. Allen, listed as a director of Cullinan Therapeutics.
What is the date of the event requiring the Form 3 filing for CGEM?
The date of the event requiring the statement is 08/07/2025.
Was the Form 3 signed and when?
The Form 3 was signed by an attorney-in-fact, Jacquelyn Sumer, on 08/08/2025.
Does the Form 3 list any derivative or non-derivative securities for CGEM?
No. The filing explicitly states no securities are beneficially owned and lists no derivative or non-derivative holdings.